Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
93.8M
-
Number of holders
-
136
-
Total 13F shares, excl. options
-
53.9M
-
Shares change
-
-1.16M
-
Total reported value, excl. options
-
$971M
-
Value change
-
-$14.3M
-
Put/Call ratio
-
19.18
-
Number of buys
-
80
-
Number of sells
-
-49
-
Price
-
$18.02
Significant Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q2 2023
156 filings reported holding CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") as of Q2 2023.
Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) has 136 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.9M shares
of 93.8M outstanding shares and own 57.45% of the company stock.
Largest 10 shareholders include Driehaus Capital Management LLC (5.3M shares), BlackRock Inc. (4.6M shares), ORBIMED ADVISORS LLC (3.95M shares), WELLINGTON MANAGEMENT GROUP LLP (3.6M shares), VANGUARD GROUP INC (2.73M shares), Bain Capital Life Sciences Investors, LLC (2.31M shares), STATE STREET CORP (2.24M shares), PERCEPTIVE ADVISORS LLC (1.95M shares), First Light Asset Management, LLC (1.56M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.43M shares).
This table shows the top 136 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.